Silence Therapeutics plc (SLN) AI Stock Analysis

Silence Therapeutics plc is a biotechnology company advancing ribonucleic acid (RNA) therapeutics in hematology, cardiovascular diseases, and rare metabolic conditions. Using its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, the company targets disease-associated genes in the liver through short interfering RNA (siRNA) molecules to degrade disease-causing messenger RNA. Its clinical pipeline includes SLN360, a Phase I candidate for cardiovascular disease linked to elevated lipoprotein levels, and SLN124, in Phase I trials for non-transfusion dependent thalassemia and myelodysplastic syndrome, with additional evaluation for polycythemia vera. Silence maintains collaborative agreements with AstraZeneca PLC, Mallinckrodt Pharma IP Trading DAC, and Hansoh Pharmaceutical Group Company Limited.

Revenue dropped 98.7% in FY2025 to $559,000, down from $43.3M in FY2024 and $25.4M in FY2023. Over the five years from FY2020 to FY2025, revenue registered a compound annual growth rate of -36.7%. The net loss expanded to -$88.6M in FY2025 compared to -$45.3M in FY2024, alongside an operating margin of -16056.0%. Research and development expenses were $67.8M in FY2025, near the $67.9M spent in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $615,000 with an operating margin of -10475.6% and diluted EPS of -$1.29, although quarterly revenue increased 197.2% year-over-year.

As of June 30, 2026, Silence Therapeutics held $72.1M in cash and short-term investments alongside total debt of $112,000, resulting in net cash of $71.9M. Total assets were $106.4M against shareholders' equity of $38.5M, supporting a current ratio of 7.42 and a debt-to-equity ratio of 0.00. In FY2025, free cash flow was -$62.3M, matching operating cash flow of -$62.3M, while capital expenditures were $55,000. Over the past five years, the company's share count changed by -46.9%.

Silence Therapeutics carries a market capitalization of $539.5M and an enterprise value of $673.9M. The stock trades at a price-to-sales multiple of 877.2x, significantly higher than the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio stands at 18.6x. Over the past year, the stock returned 31.7%, outperforming the S&P 500 (SPY) return of 16.8%. However, its five-year return of -60.2% trails the S&P 500 return of 83.0%.

Wall Street coverage includes 5 Strong Buy, 1 Buy, and 1 Strong Sell recommendations. The mean price target is $33.00, representing a 280.2% premium over the October 16, 2026 close of $8.68. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $325,010 and EPS of -$0.36. For the next fiscal year, 2 analysts expect revenue of $750,530 and EPS of -$0.38. The company beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 5, 2026.

This page is an AI-written research summary of Silence Therapeutics plc (SLN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SLN income statement, SLN balance sheet, SLN key metrics, SLN analyst forecast, SLN chart. See the SLN stock overview for the latest quote and news.